Phio Pharmaceuticals Corp. has announced key management changes as part of a strategic initiative to enhance awareness of its INTASYL siRNA portfolio. Robert Infarinato has been appointed as Vice President of Strategic Development, transitioning from his previous role as Chief Financial Officer. Lisa Carson has been named Vice President of Finance and Administration, joining Phio with over 20 years of finance and accounting leadership experience. These changes aim to focus on expanding the potential applications of the INTASYL gene silencing technology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.